Peroxiredoxin 2 Is a Potential Objective Indicator for Severity and the Clinical Status of Subarachnoid Hemorrhage Patients.
Peroxiredoxin 2 Is a Potential Objective Indicator for Severity and the Clinical Status of Subarachnoid Hemorrhage Patients.
复制标题
过氧蛋白2是严重程度和蛛网膜下腔出血患者的临床状况的潜在客观指标。
DOI：
10.1155/2023/5781180
复制
发表时间：
2023
期刊：
影响因子：
--
通讯作者：
Hang, Chun-Hua
中科院分区：
文献类型：
--
作者：
Peng, Zheng;Pang, Cong;Li, Xiao-Jian;Zhang, Hua-Sheng;Zhang, Jia-Tong;Zhu, Qi;Xu, Hua-Jie;Gao, Yong-Yue;Zhuang, Zong;Li, Wei;Zhang, Qing-Rong;Lu, Yue;Hang, Chun-Hua
我们已经证明，从溶解红细胞和受损神经元释放的过氧化物还蛋白2 （Prx2）进入蛛网膜下腔可以激活小胶质细胞，从而导致神经元凋亡。在本研究中，我们测试了Prx2作为蛛网膜下腔出血（SAH）严重程度和患者临床状态的客观指标的可能性。前瞻性纳入SAH患者，随访3个月。分别于SAH发病后0-3天和5-7天采集脑脊液和血液标本。采用酶联免疫吸附试验（ELISA）测定脑脊液和血液中Prx2的水平。我们使用Spearman等级系数来评估Prx2与临床评分之间的相关性。Prx2水平采用受试者工作特征（ROC）曲线，通过计算曲线下面积（AUC）预测SAH的预后。Unpaired Student’st检验用于分析连续变量在不同队列间的差异。发病后脑脊液中Prx2水平升高，而血液中Prx2水平降低。现有资料显示，SAH后3天内脑脊液中Prx2水平与Hunt-Hess评分呈正相关（R = 0.761, P < 0.001）。CVS患者在发病后5-7天脑脊液中Prx2水平升高。5-7天脑脊液中Prx2水平可作为预测预后的指标。发病3天内脑脊液与血液中Prx2的比值与Hunt-Hess评分呈正相关，与Glasgow结局量表呈负相关（GOS; R =‐0.605,P < 0.05）。我们发现，发病3天内脑脊液中Prx2的水平以及脑脊液中Prx2与血液的比值可以作为检测疾病严重程度和患者临床状态的生物标志物。
We have demonstrated that peroxiredoxin 2 (Prx2) released from lytic erythrocytes and damaged neurons into the subarachnoid space could activate microglia and then result in neuronal apoptosis. In this study, we tested the possibility of using Prx2 as an objective indicator for severity of the subarachnoid hemorrhage (SAH) and the clinical status of the patient. SAH patients were prospectively enrolled and followed up for 3 months. Cerebrospinal fluid (CSF) and blood samples were collected 0-3 and 5-7 days after SAH onset. The levels of Prx2 in the CSF and the blood were measured by an enzyme-linked immunosorbent assay (ELISA). We used Spearman's rank coefficient to assess the correlation between Prx2 and the clinical scores. Receiver operating characteristic (ROC) curves were used for Prx2 levels to predict the outcome of SAH by calculating the area under the curve (AUC). Unpaired Student's t-test was used to analyze the differences in continuous variables across cohorts. Prx2 levels in the CSF increased after onset while those in the blood decreased. Existing data showed that Prx2 levels within 3 days in the CSF after SAH were positively correlated with the Hunt-Hess score (R = 0.761, P < 0.001). Patients with CVS had higher levels of Prx2 in their CSF within 5-7 days after onset. Prx2 levels in the CSF within 5-7 days can be used as a predictor of prognosis. The ratio of Prx2 in the CSF and the blood within 3 days of onset was positively correlated with the Hunt-Hess score and negatively correlated with Glasgow Outcome Scale (GOS; R = ‐0.605, P < 0.05). We found that the levels of Prx2 in the CSF and the ratio of Prx2 in the CSF and the blood within 3 days of onset can be used as a biomarker to detect the severity of the disease and the clinical status of the patient.